KEVIN GAREY to Lipopeptides
This is a "connection" page, showing publications KEVIN GAREY has written about Lipopeptides.
Connection Strength
1.131
-
Innate inflammatory response and immunopharmacologic activity of micafungin, caspofungin, and voriconazole against wild-type and FKS mutant Candida glabrata isolates. Antimicrob Agents Chemother. 2015 Sep; 59(9):5405-12.
Score: 0.501
-
Micafungin pharmacodynamics predict clinical outcomes in hospitalized patients with candidemia caused by certain Candida species. Pharmacotherapy. 2023 06; 43(6):466-472.
Score: 0.216
-
Evaluating the Effects of Surotomycin Treatment on Clostridium difficile Toxin A and B Production, Immune Response, and Morphological Changes. Antimicrob Agents Chemother. 2016 06; 60(6):3519-23.
Score: 0.133
-
FKS mutant Candida glabrata: risk factors and outcomes in patients with candidemia. Clin Infect Dis. 2014 Sep 15; 59(6):819-25.
Score: 0.116
-
Evaluation of antifungal therapy in patients with candidaemia based on susceptibility testing results: implications for antimicrobial stewardship programmes. J Antimicrob Chemother. 2011 Sep; 66(9):2146-51.
Score: 0.095
-
Cadazolid for the treatment of Clostridium difficile. Expert Opin Investig Drugs. 2017 Apr; 26(4):509-514.
Score: 0.035
-
Novel antibiotics in development to treat Clostridium difficile infection. Curr Opin Gastroenterol. 2017 01; 33(1):1-7.
Score: 0.035